Anne Li 1/15/17
This week the drug olaparib (also known as Lynparza) was approved for use in Scotland for women with ovarian cancer by the Scottish Medicine’s Consortium. Scottish charity Worldwide Cancer Research funded work which kick-started the development of this drug over 20 years ago. Trials have shown the drug, can allow patients, who are often young women, with advanced ovarian cancer to live for an average of 7 months longer compared to standard treatments. Olaparib has already been approved for use in the USA and in Europe. It was also approved last year by NICE for use in England.
See original article at: https://www.worldwidecancerresearch.org/news/olaparib-approved-for-use-in-scotland/